- Home
- KOD vs CHY Comparison
KOD vs CHY Comparison
Compare KOD & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- CHY
- Stock Information
- Founded
- KOD 2009
- CHY 2003
- Country
- KOD United States
- CHY United States
- Employees
- KOD N/A
- CHY N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- CHY Investment Managers
- Sector
- KOD Health Care
- CHY Finance
- Exchange
- KOD Nasdaq
- CHY Nasdaq
- Market Cap
- KOD 795.5M
- CHY 839.8M
- IPO Year
- KOD 2018
- CHY N/A
- Fundamental
- Price
- KOD $14.09
- CHY $11.38
- Analyst Decision
- KOD Buy
- CHY
- Analyst Count
- KOD 6
- CHY 0
- Target Price
- KOD $14.33
- CHY N/A
- AVG Volume (30 Days)
- KOD 1.0M
- CHY 128.3K
- Earning Date
- KOD 11-13-2025
- CHY 01-01-0001
- Dividend Yield
- KOD N/A
- CHY 10.11%
- EPS Growth
- KOD N/A
- CHY N/A
- EPS
- KOD N/A
- CHY N/A
- Revenue
- KOD N/A
- CHY N/A
- Revenue This Year
- KOD N/A
- CHY N/A
- Revenue Next Year
- KOD N/A
- CHY N/A
- P/E Ratio
- KOD N/A
- CHY N/A
- Revenue Growth
- KOD N/A
- CHY N/A
- 52 Week Low
- KOD $1.92
- CHY $9.97
- 52 Week High
- KOD $19.39
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- KOD 56.85
- CHY 64.81
- Support Level
- KOD $13.91
- CHY $11.26
- Resistance Level
- KOD $17.12
- CHY $11.45
- Average True Range (ATR)
- KOD 2.04
- CHY 0.10
- MACD
- KOD -0.13
- CHY 0.00
- Stochastic Oscillator
- KOD 46.80
- CHY 84.37
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.